Preclinical and clinical safety data includes [5] : No evidence of mutagenic activity, chromosomal aberrations, or micronucleus formation in genotoxicity studies 6-month chronic oral administration studies in rats showed no toxicological concerns 9-month studies in cynomolgus monkeys revealed general safety Six human clinical trials spanning 0.25 mg to 30 mg doses for up to 6 months No serious adverse events or withdrawals related to AOD9604 intake No anti-AOD9604 antibodies detected, indicating low immunogenic potential No changes in vital signs, physical examinations, electrocardiograms, or safety-related laboratory parameters Research Applications A Quick Review AOD9604 is a peptide compound that has shown potential in research related to lipid metabolism, energy balance, and tissue regeneration
Crows feet can begin to develop as early as your mid-20s but most commonly become apparent by the time you are in your mid-late 30s
A B12 deficiency can also cause megaloblastic anemia, a condition where red blood cells are too large and do not function properly
And none of this research turns these compounds into a legal supplement ingredient
Use our calculator
FDA scientists recommended against adding all seven to the compounding list, citing inadequate human trials and unresolved questions about contamination, immune reactions and dosing
